期刊文献+

多孔PLGA微球的应用研究进展 被引量:6

Research progress on the application of porous PLGA microspheres
下载PDF
导出
摘要 多孔PLGA微球是一种新型的药物载体,安全无毒可生物降解,其多孔结构使其具有密度低、表面积大、表面渗透能力强等特点。同时多孔PLGA微球载药能力强,可包载亲、疏水性药物及多肽蛋白质类生物大分子药物,在药物的靶向输送、控制释放、组织再生与修复等方面研究越来越广泛。本文综述了多孔PLGA微球的制备方法及其在生物医药领域的应用,并对其发展前景进行展望。 Porous PLGA microsphere is a safe,non-toxic and biodegradable drug carrier,which possesses the characteristics of low density,large surface area,and high penetration capability due to its porous structure.Meanwhile,the porous microsphere has strong drug loading capacity so as to pack hydrophilic,hydrophobic drugs and biological macromolecular drugs.Now,this technology is widely applied in the areas of drug targeting,controlled release,as well as tissue regeneration and repair.This paper reviews the preparation methods of porous PLGA microsphere and its application in biological field.
出处 《广东药学院学报》 CAS 2012年第3期351-354,F0003,共5页 Academic Journal of Guangdong College of Pharmacy
基金 宁波市自然科学基金(2008A610095)
关键词 多孔微球 PLGA 乳化溶剂挥发法 肺部给药 porous microspheres PLGA emulsion-solvent evaporation method pulmonary delivery
  • 相关文献

参考文献36

  • 1杨晓霞,栾玉霞,蔡晓青,庞建梅,姜悦.多孔微球在医药领域的应用[J].药物生物技术,2011,18(5):449-452. 被引量:5
  • 2DEREK T, MANMOHAN S, RAJESH K. Poly ( lactide-co- glycolide ) microparticles for the development of single-dose controlled release vaccines[ J]. Adv Drug Deliver Rev, 1998,32 (10) :225 -246.
  • 3KLOSE D ,SIEPMANN F, ELKHARRAZ K, et al. How porosity and size affect the drug release mechanisms from PLGA-based microparticles[J]. Int J Pharm,2006,314( 2 ) :198 -206.
  • 4CROTYS G, PARK T G. Preparation of porous and nonporous biodegradable polymeric hollow microspheres [ J ]. J Control Release, 1995,35:91 - 105.
  • 5GIOVAGNOLI S, BLASI P, SCHOUBBEN A, et al. Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery[ J]. Ira J Pharm,2007,333(1/2) :103 -111.
  • 6AHMED A R, BODMEIER R. Preparation of preformed porous PLGA micropartieles and antisense oligonueleotides loading[ J ]. Eur J Pharm Biopharm,2009 ,71 (2) :264 - 270.
  • 7尚帅,王效义,李京京,程洪亮,陆兵.载鼠疫亚单位疫苗多孔微球的制备及其免疫效果评价[J].解放军药学学报,2010,26(4):290-292. 被引量:1
  • 8UNGARO F, ROSA G D, MIRO A, et al. Cyclodextfins in the production of large porous particles : Development of dry powders for the sustained release of insulin to the lungs [ J ]. Eur J Pharm Biopharm ,2006,28 ( 5 ) :423 - 432.
  • 9DOAN TVP, COUET W, OLIVIER J C. Formulation and in vitro characterization of inhalable fifampicin-loaded PLGA microspheres for sustained lung delivery [ J ]. lnt J Pharm, 2011,414(1/2) :112 - 117.
  • 10GUPTA V, AHSAN F. Influence of PEI as a core modifying agent on PLGA microspheres of PGE, a pulmonary selective vasodilator [ J ]. Int J Pharm,2011,413 ( 1/2 ) :51 - 62.

二级参考文献75

  • 1江荣高,王立青,刘衡,王春龙,潘卫三.干粉吸入器及其进展[J].中国药学杂志,2005,40(10):729-732. 被引量:7
  • 2江荣高,王春龙,王立青,潘卫三,刘衡.L-亮氨酸对干扰素粉雾剂性能的影响[J].中国医药工业杂志,2005,36(12):747-750. 被引量:6
  • 3江荣高,王立青,王春龙,潘卫三.影响吸入粉雾剂分散性能的制剂因素[J].中国医药工业杂志,2006,37(1):50-53. 被引量:5
  • 4江荣高,刘衡,王立青,郭红,王春龙.喷雾冷冻干燥法制备供吸入的超轻干扰素粉末[J].中国药学杂志,2007,42(5):362-364. 被引量:12
  • 5Labiris NR, Dolovich MB. Pulmonary drug delivery. Part Ⅰ: physiological factors affecting therapeutic effectiveness of aerosolized medications [J]. Br J Clin Pharmacol, 2003, 56 (6) : 588-599.
  • 6Edwards DA, Dunbar CA. Bioengineering of therapeutic aerosols [J]. Annu Rev Biomed Eng, 2002, 4: 93-107.
  • 7Koushik K, Dhanda DS, Cheruvu NP, et al. Pulmonary delivery of deslorelin: large-porous PLGA particles and HP-β CD complexes [J]. Pharm Res, 2004, 21 (7): 1119-1126.
  • 8Hardy JG, Chadwick TS. Sustained release drug delivery to the lungs: an option for the future [J]. Clin Pharmacokinet, 2000, 39(1): 1-4.
  • 9Rudt S, Wesemeyer H, Muller RH. In vitro phagocytosis assay of nano- and microparticles by chemiluminescence. Ⅳ: effect of surface modification by coating of particles with poloxamine and Antarox CO on the phagocytic uptake [J]. J Controlled Release, 1993, 25 (1-2) : 123-132.
  • 10Tabata Y, Ikada Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage [J]. Biomaterials. 1988, 9 (4) : 356-362.

共引文献8

同被引文献90

  • 1曲凤玉,朱广山,黄世英,李守贵,裘式纶.水溶性药物巯甲丙脯酸/Si-MCM-41载药新体系的制备与缓释作用研究[J].高等学校化学学报,2004,25(12):2195-2198. 被引量:16
  • 2龚明涛,张钧寿,沈益.羟基喜树碱纳米乳的制备及其抗癌作用初步研究[J].中国天然药物,2005,3(1):41-43. 被引量:25
  • 3YE X, LI J, LU M X, et al. Identification and molecular typing of Streptococcus agalactiae isolated from pond-cultured tilapia in China [J]. FishSei, 2011, 77(4): 623-632.
  • 4EVANS J J, KLESIUS P, SHOEMAKER C A, et al. Streptococcus agalactiae vaccination and infection stress in Nile tilapia, Oreochro- mis niloticus[J]. J Appl Aquac, 2005, 16(3) : 105 -115.
  • 5PRETTO L G, MULLER E E, KLESIUS P, et al. Efficacy of an experimentally inactivated Streptococcus agalactiae vaccine in Nile ti- lapia ( Oreochromis niloticus ) reared in Brazil [ J ]. Aquae Res, 2010, 41(10): 1539 -1544.
  • 6MAKADIA H K, SIEGEL S J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier [ J ]. Polymers, 2011, 3(3): 1377-1397.
  • 7JEFFERY H, DAVIS S S, OHAGAN D T. The preparation and characterization of poly ( lactide-co-glycolide ) micropariicles. 2. The entrapment of a model protein using a (water-in-oil) -in-water emulsion solvent evaporation technique [ J ]. Pharm Res, 1993, 10(3) : 362-368.
  • 8YANG Y Y, CHUNGTS, NGEE P N. Morphology, drug distri- bution, and in vitro release profiles of biodegradable polymeric mi- erospheres containing protein fabricated by double-emulsion solvent extraction/evaporation method[ Jl. Biomaterials, 2001, 22 (3) : 231 -241.
  • 9JAIN R A. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) ( PLGA ) devices [ J ]. Biomaterials, 2000, 21(23): 2475-2490.
  • 10ZIMMERMANN W H, SCHNEIDERBANGER K, SCHUBERT P, et at. Tissue engineering of a differentiated cardiac muscle con- struct[J]. Circ Res, 2002, 90(2): 223-230.

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部